Kura Oncology, Inc. (NASDAQ:KURA) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Pete De Spain - VP, IR & Corporate Communications Troy Wilson - Chairman, CEO & President Marc Grasso - CFO & Chief Business Officer Stephen Dale - Chief Medical Officer Conference Call Participants Jonathan Chang - SVB Leerink Tiago Fauth - Crédit Suisse Peter Lawson - Barclays Bank Ren Benjamin - JMP Securities Joe Pantginis - H.C. Wainwright Eva Previtera - Cowen Operator Good day, and welc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From ________ To ________ Commission file number: 001-37620 KURA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 61-1547851 (Sta ...

DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER 0 0 Corporate Presentation – September 2021 Forward-Looking Statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for tipifarnib, KO-539 and KO-2806, plans regarding regulatory filings, our expectations regarding the relative benefits of our product candidates versus competitiv ...

Kura Oncology, Inc. (NASDAQ:KURA) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Pete De Spain - VP, IR & Corporate Communications Troy Wilson - Chairman, CEO & President Marc Grasso - CFO & Chief Business Officer Conference Call Participants Jonathan Chang - SVB Leerink Peter Lawson - Barclays Bank Tiago Fauth - Crédit Suisse Reni Benjamin - JMP Securities Philip Nadeau - Cowen and Company Operator Good day, and thank you for standing by, and welcome to the Second Quarter 2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Registrant's Telephone Number, Including Area Code) (Former Name, Former Address or Former Fiscal Year If Changed Since Last Report) Securities registered pursuant to Section 12(b) of the A ...

Kura Oncology, Inc. (NASDAQ:KURA) Q1 2021 Earnings Conference Call May 6, 2021 4:30 PM ET Company Participants Pete Spain - Vice President, Investor Relations and Corporate Communications Troy Wilson - President and Chief Executive Officer Marc Grasso - Chief Financial Officer and Chief Business Officer Francis Burrows - Vice President, Translational Research Conference Call Participants Wei Chang - SVB Leerink LLC Peter Lawson - Barclays Bank PLC Reni Benjamin - JMP Securities Joseph Pantginis - H.C. Wainw ...

DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER ......... Corporate Presentation – May 2021 Forward-Looking Statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for tipifarnib and KO-539, plans regarding regulatory filings, our expectations regarding the relative benefits of our product candidates versus competitive therapi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From ________ To ________ Commission file number: 001-37620 KURA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 61-1547851 (State o ...

Kura Oncology, Inc. (NASDAQ:KURA) Q4 2020 Results Earnings Conference Call February 24, 2021 8:00 AM ET Company Participants Pete De Spain - Investor Relations Troy Wilson - President and Chief Executive Officer Marc Grasso - Chief Financial Officer Stephen Dale - Chief Medical Officer Jim Basta - Chief Legal Officer Kirsten Flowers - Chief Commercial Officer Kathy Ford - Chief Operating Officer Conference Call Participants Jonathan Chang - SVB Leerink Brian Marty Auster - Credit Suisse Peter Lawson - Barcl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37620 KURA ONCOLOGY, INC. (Exact name of Registrant as specified in its Charter) Delaware 61-1547851 (State or other jurisdiction of ...